Contemporary Applications of Machine Learning for Device Therapy in Heart Failure.
cardiac resynchronization therapy
echocardiography
heart failure
left ventricular assist device
machine learning
transcatheter edge-to-edge repair
Journal
JACC. Heart failure
ISSN: 2213-1787
Titre abrégé: JACC Heart Fail
Pays: United States
ID NLM: 101598241
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
23
05
2022
revised:
31
05
2022
accepted:
16
06
2022
entrez:
1
9
2022
pubmed:
2
9
2022
medline:
9
9
2022
Statut:
ppublish
Résumé
Despite a better understanding of the underlying pathogenesis of heart failure (HF), pharmacotherapy, surgical, and percutaneous interventions do not prevent disease progression in all patients, and a significant proportion of patients end up requiring advanced therapies. Machine learning (ML) is gaining wider acceptance in cardiovascular medicine because of its ability to incorporate large, complex, and multidimensional data and to potentially facilitate the creation of predictive models not constrained by many of the limitations of traditional statistical approaches. With the coexistence of "big data" and novel advanced analytic techniques using ML, there is ever-increasing research into applying ML in the context of HF with the goal of improving patient outcomes. Through this review, the authors describe the basics of ML and summarize the existing published reports regarding contemporary applications of ML in device therapy for HF while highlighting the limitations to widespread implementation and its future promises.
Identifiants
pubmed: 36049812
pii: S2213-1779(22)00410-3
doi: 10.1016/j.jchf.2022.06.011
pii:
doi:
Substances chimiques
Cardiovascular Agents
0
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
603-622Informations de copyright
Copyright © 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Funding Support and Author Disclosures Dr Greene has received research support from the Duke University Department of Medicine Chair’s Research Award, American Heart Association, Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Pfizer, and Sanofi; has served on advisory boards for Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Roche Diagnostics, and Sanofi; has received speaker fees from Boehringer Ingelheim; and serves as a consultant for Amgen, Bayer, Bristol Myers Squibb, Merck, PharmaIN, Sanofi, Tricog Health, Urovant Pharmaceuticals, and Vifor. Dr Al’Aref is supported by National Institutes of Health 2R01 HL12766105 and 1R21 EB030654; and has received royalty fees from Elsevier. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.